1. Signaling Pathways
  2. Apoptosis
  3. TNF Receptor

TNF Receptor (肿瘤坏死因子)

Tumor Necrosis Factor Receptor; TNFR

肿瘤坏死因子 (TNF) 是细胞凋亡以及炎症和免疫的主要介质,并且与多种人类疾病的发病机制有关,包括败血症、糖尿病、癌症、骨质疏松症、多发性硬化症、类风湿性关节炎和炎症性肠病。

TNF-α 是一种 17 kDa 蛋白质,由 157 个氨基酸组成,在溶液中为同源三聚体。在人类中,该基因位于 6 号染色体上。其生物活性主要受可溶性 TNF-α 结合受体的调节。TNF-α 主要由活化的巨噬细胞、T 淋巴细胞和自然杀伤细胞产生。已知多种其他细胞的表达较低,包括成纤维细胞、平滑肌细胞和肿瘤细胞。在细胞中,TNF-α 合成为 pro-TNF (26 kDa),它与膜结合,在 TNF 转换酶 (TACE) 裂解其 pro 结构域后释放。

许多 TNF 诱导的细胞反应是由两种 TNF 受体 TNF-R1 和 TNF-R2 中的任一种介导的,这两种受体都属于 TNF 受体超家族。在 TNF 治疗后,转录因子 NF-κB 和 MAP 激酶(包括 ERK、p38 和 JNK)在大多数类型的细胞中被激活,在某些情况下,也可能诱导细胞凋亡或坏死。然而,诱导细胞凋亡或坏死主要是通过 TNFR1 实现的,TNFR1 也称为死亡受体。NF-κB 和 MAPK 的激活在多种细胞因子和免疫调节蛋白的诱导中起着重要作用,并且对许多炎症反应至关重要。

Tumor necrosis factor (TNF) is a major mediator of apoptosis as well as inflammation and immunity, and it has been implicated in the pathogenesis of a wide spectrum of human diseases, including sepsis, diabetes, cancer, osteoporosis, multiple sclerosis, rheumatoid arthritis, and inflammatory bowel diseases.

TNF-α is a 17-kDa protein consisting of 157 amino acids that is a homotrimer in solution. In humans, the gene is mapped to chromosome 6. Its bioactivity is mainly regulated by soluble TNF-α–binding receptors. TNF-α is mainly produced by activated macrophages, T lymphocytes, and natural killer cells. Lower expression is known for a variety of other cells, including fibroblasts, smooth muscle cells, and tumor cells. In cells, TNF-α is synthesized as pro-TNF (26 kDa), which is membrane-bound and is released upon cleavage of its pro domain by TNF-converting enzyme (TACE).

Many of the TNF-induced cellular responses are mediated by either one of the two TNF receptors, TNF-R1 and TNF-R2, both of which belong to the TNF receptor super-family. In response to TNF treatment, the transcription factor NF-κB and MAP kinases, including ERK, p38 and JNK, are activated in most types of cells and, in some cases, apoptosis or necrosis could also be induced. However, induction of apoptosis or necrosis is mainly achieved through TNFR1, which is also known as a death receptor. Activation of the NF-κB and MAPKs plays an important role in the induction of many cytokines and immune-regulatory proteins and is pivotal for many inflammatory responses.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N0619
    Mulberroside A

    桑皮苷 A

    Inhibitor 99.86%
    Mulberroside A 是桑树 (Morus alba L.) 中的主要生物活性成分之一。Mulberroside A 可降低 TNF-αIL-1βIL-6 的表达,抑制 NALP3,caspase-1NF-κB 的激活以及 ERKJNK 和 p38 的磷酸化 。Mulberroside A 具有抗炎和抗细胞凋亡作用。Mulberroside A 对蘑菇酪氨酸酶 ( tyrosinase) 具有抑制活性,IC50 为 53.6 μM。
    Mulberroside A
  • HY-N6739
    Beauvericin

    白僵菌素

    99.97%
    Beauvericin 是一种环六肽镰刀菌毒素,具有杀虫、抗菌、抗癌、抗病毒和细胞毒活性。Beauvericin 通过产生 DNA 断裂、染色体畸变和微核,造成细胞的遗传毒性,并抑制 PI3K/AKT 通路诱导细胞凋亡 (apoptosis),从而抑制 HCC 的生长。此外,Beauvericin 通过抑制淋巴细胞增殖和干扰人单核细胞向巨噬细胞的分化过程,来影响免疫功能。
    Beauvericin
  • HY-N6607
    Tryptanthrin Modulator 99.89%
    Tryptanthrin 是一种吲哚喹唑啉,可以是产自靛蓝植物的生物碱。Tryptanthrin 是一种口服有效的细胞白三烯 (LT) 生物合成抑制剂。Tryptanthrin 具有抗癌活性。Tryptanthrin 可抑制 NOS1、COX-2、NF-κB 的表达水平,调节 IL-2、IL-10、TNF-α 的表达水平。
    Tryptanthrin
  • HY-N1949
    Homoplantaginin

    高车前苷

    Inhibitor 99.90%
    Homoplantaginin是来自中药Salvia plebeia的具有抗炎和抗氧化活性的类黄酮。
    Homoplantaginin
  • HY-N2963
    Broussonin E Inhibitor 98.18%
    Broussonin E 是一种酚类化合物,具有抗炎活性。Broussonin E 可以通过抑制 ERKp38 MAPK,增强 JAK2-STAT3 信号通路,调节巨噬细胞的激活状态来抑制炎症。Broussonin E 可用于动脉粥样硬化等炎症相关疾病的研究。
    Broussonin E
  • HY-147045
    UCB-5307 Inhibitor
    UCB-5307 是一种 TNF 抑制剂,对人 TNFα 的 KD 为 9 nM。UCB-5307 可以穿透预制的 hTNF/hTNFR1 复合物。
    UCB-5307
  • HY-100755
    KR-33493 Inhibitor 99.94%
    KR-33493 是一个有效的 Fas 介导细胞死亡 (FAF1) 的抑制剂。
    KR-33493
  • HY-N0604
    Ginsenoside Rh1

    人参皂苷 Rh1

    Inhibitor 98.72%
    Ginsenoside Rh1 (Prosapogenin A2) 抑制 PPAR-γTNF-αIL-6IL-1β 的表达。
    Ginsenoside Rh1
  • HY-N0512
    Loganin

    马钱子苷

    Inhibitor 99.85%
    Loganin 是一种环烯醚萜苷类化合物,具有抗炎、抗氧化、抗肿瘤并对急性肺损伤和肺纤维化具有保护作用。Loganin 通过上调 Nrf2/HO-1 信号通路发挥其对 LPS (HY-D1056) 介导的炎症和氧化应激的保护作用,并减少脊髓损伤 (SCI) 引起的神经炎症。
    Loganin
  • HY-P99260
    Conatumumab Agonist 98.90%
    Conatumumab (AMG 655) 是一种针对人死亡受体 5 (DR5,TRAILR2) 的单克隆激动剂抗体 (Kd: 长型 DR5 为 1 nM, 短型 DR5 为 0.8 nM)。Conatumumab 通过激活 caspase 诱导细胞凋亡 (apoptosis)。Conatumumab 可用于癌症研究。
    Conatumumab
  • HY-N2350
    Cynaropicrin

    菜蓟苦素

    Inhibitor 99.79%
    Cynaropicrin 是一种倍半萜内酯,可以抑制肿瘤坏死因子 (TNF-α) 的释放,在鼠和人巨噬细胞的 IC50 值分别为 8.24 和 3.18 μM。 Cynaropicrin 也抑制软骨降解因子 (MMP13) 的增加并抑制 NF-κB 的信号传导。
    Cynaropicrin
  • HY-101849
    Fasentin Agonist ≥98.0%
    Fasentin 是有效的葡萄糖摄取抑制剂,可抑制 GLUT-1/GLUT-4 转运蛋白。Fasentin 优先抑制 GLUT4 (IC50=68 μM)。Fasentin 是死亡受体刺激 (FAS) 敏化剂,可敏化细胞对 FAS 诱导的细胞死亡。Fasentin 也是诱导肿瘤坏死因子 (TNF) 凋亡配体的敏化剂。Fasentin 阻断癌细胞系中的葡萄糖摄取,并具有抗血管生成活性。
    Fasentin
  • HY-107390
    AX-024 Inhibitor 99.29%
    AX-024 是一种口服可利用的,首创的 TCR-Nck 相互作用抑制剂,可选择性地抑制 TCR 触发的 T 细胞活化,IC50 值为 1 nM。AX-024 通过靶向 SH3 结构域调节细胞信号传导。AX-024 具有低毒、高效、高选择性的特点。AX-024 有效抑制白细胞介素-6 (IL-6),肿瘤坏死因子-α (TNFα),干扰素-γ (IFN-γ),IL-10IL-17A 的产生。
    AX-024
  • HY-15509A
    Semapimod tetrahydrochloride Inhibitor 98.43%
    Semapimod tetrahydrochloride (CNI-1493) 是促炎细胞因子产生 (proinflammatory cytokine) 的抑制剂,可抑制TNF-αIL-1βIL-6。Semapimod tetrahydrochloride 抑制巨噬细胞 p38 MAPK 和一氧化氮生成。Semapimod tetrahydrochloride 抑制 TLR4 信号 (IC50≈0.3 μM)。Semapimod tetrahydrochloride 在多种炎症和自身免疫性疾病中具有潜在的作用。
    Semapimod tetrahydrochloride
  • HY-101448
    TMI-1 Inhibitor 99.59%
    TMI-1 (WAY-171318) 是可口服的肿瘤坏死因子转换酶 (TACE) 抑制剂 (IC50: 8.4 nM),也是 ADAM-TS-4ADAM-17 及多种 MMPs 的有效抑制剂。TMI-1 能显著抑制 TNF-α 的分泌,减轻小鼠胶原诱导关节炎。TMI-1 抑制肿瘤增殖,通过 Caspase 依赖途径诱导凋亡。TMI-1 还逆转 TRPV1 上调并降低神经细胞内炎症因子 (TNF-αIL-1βIL-6) 水平,保护免受紫杉醇引起的神经毒性。TMI-1 导致促动脉粥样硬化脂蛋白谱变化,但不影响早期病变进展。
    TMI-1
  • HY-150725
    ODN 1585 Inducer
    ODN 1585 是一种有效的 IFNTNFα 产生诱导剂。ODN 1585 是一种有效的 NK (自然杀手)刺激剂。ODN 1585 增加 CD8+ T 细胞的功能,包括 CD8+ T 细胞介导的 IFN-γ 的产生。ODN 1585诱导小鼠已建立的黑色素瘤消退。ODN 1585 对小鼠的疟疾具有完全的保护作用。ODN 1585 可用于急性骨髓性白血病 (AML) 和疟疾研究。ODN 1585 可作为疫苗佐剂。
    ODN 1585
  • HY-N2119
    Sciadopitysin

    金松双黄酮

    ≥99.0%
    Sciadopitysin 是一种来自银杏叶片中的双黄酮类化合物。Sciadopitysin 通过抑制 NF-κB 活化并降低 c-FosNFATc1 的表达来抑制 RANKL 诱导的破骨细胞生成和骨丢失。
    Sciadopitysin
  • HY-P1068
    Lysozyme

    溶菌酶

    Inhibitor
    Lysozyme (Muramidase) 是一种保守的抗微生物蛋白。Lysozyme 通过水解细菌细胞壁肽聚糖 (PG) 来发挥杀菌作用。Lysozyme 在限制粘膜表面和其他部位的细菌生长方面起着重要作用,它不仅可以控制潜在的致病菌,还可以限制微生物群的过度生长以防止生态失调。胞外 Lysozyme 还可将多聚 PG 降解为可溶片段,激活粘膜上皮细胞中的 NOD 受体,导致中性粒细胞和巨噬细胞分泌趋化因子和激活因子。
    Lysozyme
  • HY-P99670
    Iscalimab

    伊卡利单抗

    Inhibitor 99.64%
    Iscalimab (CFZ-533) 是一种非耗竭性 IGg1 单克隆抗体,靶向 CD40 (KD: 0.3 nM)。Iscalimab 可用于 Graves 甲状腺功能亢进症和自身免疫性疾病的研究。
    Iscalimab
  • HY-P99459
    Baminercept

    贝奈西普

    99.9%
    Baminercept (BG 9924) 是一种抗淋巴毒素 β 受体 (LTβR) IgG 融合蛋白 (LTβR-Ig)。Baminercept 可选择性结合 LTβR 的配体 LTα/β 异三聚体及 LIGHT,阻断 LTβR 信号通路,抑制 CXCL13 等趋化因子表达。Baminercept 能够调节外周血 B 细胞和 T 细胞亚群,减少 IFN 诱导基因的转录,从而抑制淋巴组织中高内皮微静脉和网状结构的形成,影响免疫细胞迁移。Baminercept 可用于原发性干燥综合征 (pSS)、类风湿关节炎 (RA) 等自身免疫性疾病的研究。
    Baminercept
目录号 产品名 / 同用名 种属 表达系统
目录号 产品名 / 同用名 应用 反应物种

Following the binding of TNF to TNF receptors, TNFR1 binds to TRADD, which recruits RIPK1, TRAF2/5 and cIAP1/2 to form TNFR1 signaling complex I; TNFR2 binds to TRAF1/2 directly to recruit cIAP1/2. Both cIAP1 and cIAP2 are E3 ubiquitin ligases that add K63 linked polyubiquitin chains to RIPK1 and other components of the signaling complex. The ubiquitin ligase activity of the cIAPs is needed to recruit the LUBAC, which adds M1 linked linear polyubiquitin chains to RIPK1. K63 polyubiquitylated RIPK1 recruits TAB2, TAB3 and TAK1, which activate signaling mediated by JNK and p38, as well as the IκB kinase complex. The IKK complex then activates NF-κB signaling, which leads to the transcription of anti-apoptotic factors-such as FLIP and Bcl-XL-that promote cell survival. 

 

The formation of TNFR1 complex IIa and complex IIb depends on non-ubiquitylated RIPK1. For the formation of complex IIa, ubiquitylated RIPK1 in complex I is deubiquitylated by CYLD. This deubiquitylated RIPK1 dissociates from the membrane-bound complex and moves into the cytosol, where it interacts with TRADD, FADD, Pro-caspase 8 and FLIPL to form complex IIa. By contrast, complex IIb is formed when the RIPK1 in complex I is not ubiquitylated owing to conditions that have resulted in the depletion of cIAPs, which normally ubiquitylate RIPK1. This non-ubiquitylated RIPK1 dissociates from complex I, moves into the cytosol, and assembles with FADD, Pro-caspase 8, FLIPL and RIPK3 (but not TRADD) to form complex IIb. For either complex IIa or complex IIb to prevent necroptosis, both RIPK1 and RIPK3 must be inactivated by the cleavage activity of the Pro-caspase 8-FLIPL heterodimer or fully activated caspase 8. The Pro-caspase 8 homodimer generates active Caspase 8, which is released from complex IIa and complex IIb. This active Caspase 8 then carries out cleavage reactions to activate downstream executioner caspases and thus induce classical apoptosis. 

 

Formation of the complex IIc (necrosome) is initiated either by RIPK1 deubiquitylation mediated by CYLD or by RIPK1 non-ubiquitylation due to depletion of cIAPs, similar to complex IIa and complex IIb formation. RIPK1 recruits numerous RIPK3 molecules. They come together to form amyloid microfilaments called necrosomes. Activated RIPK3 phosphorylates and recruits MLKL, eventually leading to the formation of a supramolecular protein complex at the plasma membrane and necroptosis [1][2].

 

Reference:
[1]. Brenner D, et al. Regulation of tumour necrosis factor signalling: live or let die.Nat Rev Immunol. 2015 Jun;15(6):362-74. 
[2]. Conrad M, et al. Regulated necrosis: disease relevance and therapeutic opportunities.Nat Rev Drug Discov. 2016 May;15(5):348-66. 
 

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.